Table 2.

Clinical data of COVID-19 severe patients according to outcome after ICU care. The survivor group was younger than the non-survivor group and the sex distribution was similar between both groups. In the non-survivor group there was a significantly higher prevalence of hypertension diabetes, cardiovascular diseases and dialysis, higher BMI and, AKI. The other parameters such as days of symptoms, length of ICU stay, pre-hospitalization iRAAS use, in hospital corticosteroid use, SAPS3 and SOFA scores at hospital admission, PO2/FiO2 ratio, white cell blood counts, RCP, creatinine, bilirubin, and lactate were not statistically different between survivor groups and non-survivor groups. Clinical data are expressed as mean ± standard error of mean. BMI=Body max index, RCP=Reactive C-Protein.

	Survivors (n = 30)	Non-survivors (n = 23)	p
Age	56.1 ± 2.2.	64.0 ± 2.4 *	0.0223
Male sex	20 (66.7%)	16 (69.6%)	0.823
Diabetes	2 (6.7%)	8 (34.8%) *	0.009
Hypertension	11 (36.6%)	18 (78.3%) *	0.006
BMI, kg/m2	29.7 ± 1	33.7 ± 2 *	0.0442
CVD	7 (23.3%)	12 (52.2%) *	0.03
iRAAS prehospitalization	13 (43.3%)	11 (47.8%)	0.744
Days of symptoms	9.7 ± 1	10.4 ± 2	0.581
Days from symptoms worsening	2.7 ± 1	3.2 ± 1	0.333
SAPS3	58.3 ± 2.1	61.2 ± 2.2	0.432
SOFA	8.2 ± 0.5	9.6 ± 0.7	0.067
Hospitalization days	17.5 ± 3	13.6 ± 2	0.692
In hospital corticoid use	26 (86.7%)	21 (91.30%)	0.597
PaO2/FiO2, ratio	138.4 ± 20	138.3 ± 19	0.996
Leukocytes	10.6 ± 0.8	10.9 + 0.95	0.805
Neutrophiles	8.4 + 0.8	9.3 + 0.91	0.459
Lymphocytes x10/ mm3	1.2 + 0.1	0.9 + 0.2	0.259
Platelets x 103/l	250 ± 150	234 ± 23	0.532
Bilirubin (mg/dL)	0.54 ± 0.1	1.14 ± 0.3	0.0547
Creatinine (mg/dL)	1.50 ± 0.2	1.65 ± 0.2	0.244
Lactate (mg/dL)	2.19 ± 0.1	2.37 ± 0.2	0.58
CRP (mg/dL)	12.55 ± 1.5	13.20 ± 1.7	0.775
AKI (mg/dL)	11(36.7%)	15(65.2%) *	0.039
Dialysis	4(13.3%)	13(56.5%) *	0.0008